Guselkumab Shows Consistent Safety Profile With Up to 5 Years of Continuous Treatment
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of the American Academy of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Consistent safety profile with up to five years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
J Am Acad Dermatol 2021 Nov 16;[EPub Ahead of Print], A Blauvelt, TF Tsai, RG Langley, M Miller, YK Shen, Y You, YW Yang, KA Papp, L PuigFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.